Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Mulls Biz Platform after Olmesartan LOE: New 5 Year Plan
March 25, 2013
- Takeda Returns Global Rights to NPS Pharmaceuticals for Preotact and Revestive
March 25, 2013
- Israeli-Originated High-Techs Highlighted at Israel Life Science Forum 2013
March 25, 2013
- Merck Serono to Develop Anticancer Drugs for Asian Patients at R&D Hub in Tokyo
March 22, 2013
- New Product Launches “On Track,” Sales Brisk: Otsuka Holdings Pres. Higuchi
March 22, 2013
- SSRI Predicts SGLT-2 Inhibitor Market to Grow to around 60 Billion Yen in 5th Year after Launch
March 22, 2013
- Japan Pharmas Accelerating Drives to Set Up Medical Affairs Units
March 21, 2013
- MHLW Lifts All-Case Surveillance for Treakisym: SymBio, Eisai
March 19, 2013
- Alcon Japan, Kyowa Kirin Adjust Shipments of Anti-Allergy Drugs
March 19, 2013
- Daiichi Sankyo to File Prasugrel for Cardiovascular Disease in PCI Patients in Japan
March 19, 2013
- Pfizer Japan Launches OAB Treatment Toviaz
March 19, 2013
- Generic Companies Increasing Focus on Fast-growing Oncology Market; Shift to Overseas Production Will Spur Cost Competition
March 18, 2013
- Eisai Appoints Its First Female Executive
March 18, 2013
- MHLW Lifts All-Case Surveillance for Novartis' Lucentis
March 18, 2013
- Nihon Pharmaceutical Industry Voluntarily Recalls Revinbace Tablets 10 mg, Temporarily Suspends Sales
March 18, 2013
- Eisai Eyes Sales of 50 Billion Yen in Asian Generic Biz within 5 Years
March 15, 2013
- Shionogi, Kyoto University to Collaborate on Research for AD Treatment
March 15, 2013
- Eli Lilly Japan Files Tadalafil for BPH, 3rd NDA for Same API
March 15, 2013
- Astellas Files NDA in Japan for SGLT-2 Inhibitor Ipragliflozin
March 15, 2013
- API Corporation to Establish Production Base for Drug Substances, Intermediates in India
March 15, 2013
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…